In the last decades, technologies became more complex which increased the degree of uncertainty in R&D. To overcome the uncertainty, firms frequently engage in R&D collaborations, e.g., Research Joint Ventures (RJVs), and licensing agreements. While RJVs are well explored in the literature, very...

Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...

Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D investments...

Complex high technology industries are increasingly affected by patent thickets in which firms' patents mutually block the use of important technologies. Firms facing patent thickets patent intensively to acquire bargaining chips and use licensing to ensure freedom to operate. Such licensing...

In the last ten years, the pharmaceutical industry has experienced steep, unprecedented price increases. Pharmaceutical companies engage in R&D cooperations to cope with rocketing research and development (R&D) expenses.We study the impact of R&D cooperations on firms' research activities and...

Using a novel database on prediscovery licensing agreements (one type of R&D cooperation) as well as detailed firm-level and semiconductor market-specific information, we estimate the impact of prediscovery licensing agreements (PDLAs) on innovation and product market efficiency. Our results...